HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lantry, L. E. Articles by Nunn, A. D. Search for Related Content PubMed PubMed Citation Articles by Lantry, L. E. Articles by Nunn, A. D.

¹⁷⁷Lu-AMBA: Synthesis and Characterization of a Selective ¹⁷⁷Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer

¹ Ernst Felder Laboratories, Bracco Research USA Inc., Princeton, New Jersey; ² Bracco Imaging S.p.A., Milan, Italy; and ³ Institute of Pathology, University of Bern, Bern, Switzerland

Correspondence: For correspondence or reprints contact: Laura E. Lantry, PhD, Discovery Biology, Ernst Felder Laboratories, Bracco Research USA Inc., 305 College Rd. East, Princeton, NJ 08540-6608. E-mail: Laura.Lantry{at}bru.bracco.com

Gastrin-releasing peptide receptors (GRP-R) are upregulated in many cancers, including prostate, breast, and lung. We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiotherapy that has improved pharmacokinetics (PK) and better retention of radioactivity in the tumor. Methods: DO3A-CH₂CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH₂ (AMBA) was synthesized and radiolabeled. The human prostate cancer cell line PC-3 was used to determine the binding (K_d), retention, and efflux of ¹⁷⁷Lu-AMBA. Receptor specificity was determined by in vitro autoradiography in human tissues. PK and radiotherapy studies were performed in PC-3 tumor-bearing male nude mice. Results: ¹⁷⁷Lu-AMBA has a high affinity for the GRP-R (K_d, 1.02 nmol/L), with a maximum binding capacity (B_max) of 414 fmol/10⁶ cells (2.5 x 10⁵ GRP-R/cell). Internalization was similar for ¹⁷⁷Lu-AMBA (76.8%), ¹⁷⁷Lu-BBN8 (72.9%), and ¹²⁵I-[Tyr⁴]-BBN (74.9%). Efflux was markedly lower for ¹⁷⁷Lu-AMBA (2.9%) compared with ¹⁷⁷Lu-BBN8 (15.9%) and ¹²⁵I-[Tyr⁴]-BBN (46.1%). By receptor autoradiography, Lu-AMBA binds specifically to GRP-R (0.8 nmol/L) and to the neuromedin B receptor (NMB-R) (0.9 nmol/L), with no affinity for the bb3 receptor (>1,000 nmol/L). ¹⁷⁷Lu-AMBA was renally excreted (55 %ID 1 h [percentage injected dose at 1 h]); tumor uptake at 1 and 24 h was 6.35 %ID/g and 3.39 %ID/g, respectively. One or 2 doses of ¹⁷⁷Lu-AMBA (27.75 MBq/dose) significantly prolonged the life span of PC-3 tumor-bearing mice (P < 0.001 and P < 0.0001, respectively) and decreased PC-3 tumor growth rate over controls. When compared using World Health Organization criteria, mice receiving 2 doses versus 1 dose of ¹⁷⁷Lu-AMBA demonstrated a shift away from stable/progressive disease toward complete/partial response; by RECIST (Response Evaluation Criteria in Solid Tumors), median survival increased by 36% and time to progression/progression-free survival increased by 65%. Conclusion: ¹⁷⁷Lu-AMBA binds with nanomolar affinity to GRP-R and NMB-R, has low retention of radioactivity in kidney, demonstrates a very favorable risk–benefit profile, and is in phase I clinical trials.

Key Words: gastrin-releasing peptide • prostate cancer • experimental radiotherapeutics • ¹⁷⁷Lu • preclinical

Related articles in JNM:

This Month in JNM

JNM 2006 47: 11a-12a. [Full Text]  

This article has been cited by other articles:

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]

				R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, and J. C. Reubi Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting J. Nucl. Med., February 1, 2008; 49(2): 318 - 326. [Abstract] [Full Text] [PDF]

				D. Cornelio, R Roesler, and G Schwartsmann Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Onc., September 1, 2007; 18(9): 1457 - 1466. [Abstract] [Full Text] [PDF]

				J. C. Garrison, T. L. Rold, G. L. Sieckman, S. D. Figueroa, W. A. Volkert, S. S. Jurisson, and T. J. Hoffman In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems J. Nucl. Med., August 1, 2007; 48(8): 1327 - 1337. [Abstract] [Full Text] [PDF]